Acara, Ahmet ÇağdaşBolatkale, MustafaKızıloğlu, İlkerİbişoğlu, ErsinCan, Çagdaş10.07.20192019-07-1010.07.20192019-07-102018Acara, A., Bolatkale, M., Kızıloğlu, İ., İbişoğlu, E. ve Can, Ç. (2018). A novel biochemical marker for predicting the severity of ACS with unstable angina pectoris: Asprosin. American Journal of Emergency Medicine, 36(8), 1504-1505. https://dx.doi.org/10.1016/j.ajem.2017.12.0320735-67571532-8171https://dx.doi.org/10.1016/j.ajem.2017.12.032https://hdl.handle.net/20.500.12511/1975WOS: 000439103800039PubMed ID: 29274804Ischemic Heart Disease (IHD) is the leading cause of death world-wide, accounting for 12.7% of global mortality[1] . Acute Coronary Syn-drome (ACS) covers a wide spectrum of clinical conditions ranging fromunstable angina to Non-ST Elevation Myocardial Infarction (N-STEMI)and ST Elevation Myocardial Infarction (STEMI). New treatments andmanagement guidelines emerge for the care of patients with ACS; riskstratification is the cornerstone in the initial evaluation of these patients[2] . That inflammatory mediators play a role duringthe evolution of ACSis indicated by the widespread coronary inflammation found during un-stable angina pectoris (UAP), throughout theentire coronary artery bed,and in the extent that ACS outcome is related to a concurrent inflamma-toryresponse[3,4] . Circulatingasprosin,a protein hormone, responds tolow dietary glucose by triggering the release of liver glucose stores, andthe reduction of asprosin protects against the hyperinsulinism associat-ed with metabolic syndrome.eninfo:eu-repo/semantics/embargoedAccessAsprosinBiochemical MarkerAngina PectorisLetter3681504150510.1016/j.ajem.2017.12.032Q2Q1